The Washington Post: Brenda Fitzgerald, director of the Centers for Disease Control and Prevention, at agency headquarters in Atlanta on Dec. 5. (Melissa Golden for The Washington Post) ATLANTA — After five months in office, President Trump’s new director of the Centers for Disease Control and Prevention has been unable to divest financial holdings that pose potential conflicts of interest, hindering her ability to fully perform her job. Brenda Fitzgerald, 71, who served as the Georgia public health commissioner until her appointment to the CDC post in July, said she has divested from many stock holdings. But she and her husband are legally obligated to maintain other investments in cancer detection and health information technology, according to her ethics agreement, requiring Fitzgerald to pledge to avoid government business that might affect those interests. Fitzgerald provided The Post with a copy of her agreement. Last week, Sen. Patty Murray (D-Wash.), the senior Democrat on the Senate committee that oversees CDC, wrote that Fitzgerald is raising questions about her ability to function effectively. “I am concerned that you cannot perform the role of CDC director while being largely recused from matters pertaining to cancer and opioids, two of the most pervasive and urgent health challenges we face as a country,” Murray wrote. By her reading of the ethics agreement, Murray wrote, Fitzgerald is unable to engage in “key matters relating to cancer,” the second leading cause of death in the United States.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now